These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 9577019)

  • 41. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety.
    Mallet E; Belohradsky BH; Lagos R; Gothefors L; Camier P; Carrière JP; Kanra G; Hoffenbach A; Langue J; Undreiner F; Roussel F; Reinert P; Flodmark CE; Stojanov S; Liese J; Levine MM; Muñoz A; Schödel F; Hessel L;
    Vaccine; 2004 Mar; 22(11-12):1343-57. PubMed ID: 15063556
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Evaluation of the reactogenicity and immunogenic potency of combined vaccine "Bubo-Kok" in the immunization of children against diphtheria, tetanus, pertussis and viral hepatitis B].
    Fel'dblium IV; Nikolaeva AM; Kuz'ianin AV; Borisova VN; Mel'nikov VA; Chuprinina RP; Perelygina OV; Shalunova NV; Semenova VD; Griaznova DV; Pushkareva EV; Uvitskiĭ AIu; Alekseeva IA; Konopleva OA; Budanov MV; Iakovleva IM
    Zh Mikrobiol Epidemiol Immunobiol; 2004; (5):58-62. PubMed ID: 15554315
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine.
    Black S; Greenberg DP
    Expert Rev Vaccines; 2005 Dec; 4(6):793-805. PubMed ID: 16372875
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of an acellular pertussis vaccine booster in 15- to 20-month-old children previously immunized with acellular or whole-cell pertussis vaccine as infants.
    Pichichero ME; Francis AB; Marsocci SM; Green JL; Disney FA; Meschievitz C
    Pediatrics; 1993 Apr; 91(4):756-60. PubMed ID: 8464662
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acellular pertussis vaccination of 2-month-old infants in the United States.
    Pichichero ME; Francis AB; Blatter MM; Reisinger KS; Green JL; Marsocci SM; Disney FA
    Pediatrics; 1992 May; 89(5 Pt 1):882-7. PubMed ID: 1579399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary vaccination of infants with a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine.
    Kanra G; Ceyhan M; Ecevit Z; Bogaerts H; De Grave D; Hauser P; Desmons P
    Pediatr Infect Dis J; 1995 Nov; 14(11):998-1000. PubMed ID: 8584369
    [No Abstract]   [Full Text] [Related]  

  • 50. [The immunogenicity of vaccines against diphtheria, tetanus, pertussis and polio administered orally on the vaccinal calendar at the age of 2, 4 and 6 months and their coadministration with a hepatitis B vaccine at 0, 2 and 6 months].
    Arístegui Fernández J; Muñiz Saitua J; Pérez Legorburu A; Imaz Pérez M; Arrate Zugazabeitia JP; Suárez Fernández MD; Goiri Zabala MD
    An Esp Pediatr; 1996 Jan; 44(1):25-8. PubMed ID: 8849056
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis B component does not interfere with the immune response to diphtheria, tetanus and whole-cell Bordetella pertussis components of a quadrivalent (DTPw-HB) vaccine: a controlled trial in healthy infants.
    Diez-Delgado J; Dal-Ré R; Llorente M; González A; López J
    Vaccine; 1997; 15(12-13):1418-22. PubMed ID: 9302754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A simplified schedule to integrate the hepatitis B vaccine into an expanded program of immunization in endemic countries.
    Lee CY; Lee PI; Huang LM; Chen JM; Chang MH
    J Pediatr; 1997 Jun; 130(6):981-6. PubMed ID: 9202623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A combined liquid Hib (PRP-OMP), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: uncontrolled preliminary clinical trial of immunogenicity and reactogenicity.
    Nolan T; Hogg G; Darcy MA; Skeljo M; Carlin J
    Vaccine; 1998 Dec; 16(20):2085-9. PubMed ID: 9796068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diphtheria, tetanus and whole cell pertussis vaccine combined with hepatitis B vaccines: a comparison of two doses (10 microg and 5 microg).
    Chiu HH; Huang LM; Lee PI; Safary A; Lee CY
    Pediatr Infect Dis J; 1998 Mar; 17(3):206-11. PubMed ID: 9535247
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine administered according to two different primary vaccination schedules. Multicenter Working Group.
    Giammanco G; Moiraghi A; Zotti C; Pignato S; Li Volti S; Giammanco A; Soncini R
    Vaccine; 1998 Apr; 16(7):722-6. PubMed ID: 9562692
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Newborn universal immunisation against hepatitis B: immunogenicity and reactogenicity of simultaneous administration of diphtheria/tetanus/pertussis (DTP) and oral polio vaccines with hepatitis B vaccine at 0, 2 and 6 months of age.
    Aristegui J; Muñiz J; Pérez Legorburu A; Imaz M; Arrate JP; Suárez MD; Goiri MD
    Vaccine; 1995 Aug; 13(11):973-7. PubMed ID: 8525690
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine.
    Stehr K; Cherry JD
    Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571
    [No Abstract]   [Full Text] [Related]  

  • 58. Immune response to a combined hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine administered to infants at 2, 4 and 6 months of age.
    Aristegui J; Garrote E; González A; Arrate JP; Perez A; Vandepapelière P
    Vaccine; 1997 Jan; 15(1):7-9. PubMed ID: 9041659
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying.
    Blumberg DA; Lewis K; Mink CM; Christenson PD; Chatfield P; Cherry JD
    Pediatrics; 1993 Jun; 91(6):1158-65. PubMed ID: 8502521
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibodies to diphtheria, tetanus and pertussis in infants before and after immunization with DTP (Triple Antigen) vaccine.
    Stewart TA; Nolan TM; Hogg G; McEwen J
    J Paediatr Child Health; 1996 Oct; 32(5):378-81. PubMed ID: 8933394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.